Table 3.
Variation in Plan and Out-of-Pocket Payment Amounts Across Initial Treatment Strategy
| Initial treatment regimen | No. of patients needing retreatment | Average net payment, USD (SD) | Average out-of-pocket payment, USD (SD) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Initial treatment | First retreatment | Second retreatment | Third retreatment | Initial retreatment | First retreatment | Second retreatment | Third retreatment | ||
| SOF | 393 | $95,277 (50,655) | $128,789 (69,367) | $97,112 (63,618) | $70,068 (.) | $1,205 (5,211) | $1,304 (3,902) | $616 (1,065) | $75 (.) |
| SOF/LDV | 279 | $74,977 (48,692) | $85,119 (58,811) | $94,303 (44,351) | — | $1,349 (4,555) | $1,668 (7,959) | $1,341 (3,228) | — |
| SOF+SMV | 157 | $131,448 (46,708) | $139,676 (58,266) | $164,034 (100,836) | — | $1,344 (5,261) | $1,418 (6,537) | $846 (1,137) | — |
| OBV/PTV/RTV and DSV | 116 | $54,340 (38,836) | $84,090 (39,772) | $75,309 (19,740) | — | $617 (2,192) | $720 (2,403) | $615 (1,173) | — |
| SOF/VEL | 39 | $51,480 (29,818) | $54,442 (19,074) | — | — | $750 (1,588) | $611 (1,979) | — | — |
| SOF+DCV | 15 | $147,239 (38,953) | $78,001 (25,963) | — | — | $609 (760) | $262 (269) | — | — |
| GLE/PIB | 13 | $21,683 (9,991) | $65,481 (28,875) | — | — | $1,884 (3,980) | $114 (93) | — | — |
| GRZ/EBR | 5 | $50,874 (20,403) | $83,762 (59,858) | — | — | $1,056 (2,087) | $896 (1,559) | — | — |
| Average spending among all re-treated patients | 1,017 | $88,550 (53,435) | $109,915 (65,211) | $97,106 (58,317) | $70,068 (.) | $1,181 (4,618) | $1,304 (5,531) | $815 (1,819) | $75 (.) |
DCV = daclatasvir; DSV = dasabuvir; EBR = elbasvir; GLE = glecaprevir; GRZ = grazoprevir; LDV = ledipasvir; OBV = ombitasvir; PIB = pibrentasvir; PTV = paritaprevir; RTV = ritonavir; SMV = simeprevir; SOF = sofosbuvir; USD = US dollar; VEL = velpatasvir; VOX = voxilaprevir.